Clopidogrel Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Comparison of the Initial TIMI Flow Grade in Acute ST-Elevation Myocardial Infarction Patients Receiving Ticagrelor vs. Clopidogrel before Undergoing Primary Percutaneous Coronary Intervention: A Prospective Cohort Study
CONCLUSION: In STEMI patients who were candidates for primary PCI, ticagrelor administration led to a better initial TIMI flow grade compared to clopidogrel.PMID:38348469 | PMC:PMC10861275 | DOI:10.1155/2024/6632656 (Source: Cardiology Research and Practice)
Source: Cardiology Research and Practice - February 13, 2024 Category: Cardiology Authors: Amin Elahifar Ali Rafati Mohammad Javad Alemzadeh-Ansari Yeganeh Pasebani Behshad Naghshtabrizi Younes Mohammadi Seyed Kianoosh Hosseini Source Type: research

Differential effect of ticagrelor versus clopidogrel by homocysteine levels on risk of recurrent stroke: a post hoc analysis of the CHANCE-2 trial
CMAJ. 2024 Feb 11;196(5):E149-E156. doi: 10.1503/cmaj.231262.ABSTRACTBACKGROUND: Elevated homocysteine levels are associated with increased blood coagulation and platelet activity and may modulate the response to antiplatelet therapies. We aimed to investigate the effects of homocysteine levels on the efficacy and safety of ticagrelor-acetylsalicylic acid (ASA) versus clopidogrel-ASA among patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles.METHODS: We conducted a post hoc analysis of the CHANCE-2 (The Clopidogrel in High-risk Patients with Acute Nondisabling Cerebrovascular...
Source: cmaj - February 12, 2024 Category: General Medicine Authors: Anxin Wang Xue Tian Xuewei Xie Hao Li Philip M Bath Jing Jing Jinxi Lin Yilong Wang Xingquan Zhao Zixiao Li Liping Liu Yongjun Wang Xia Meng Source Type: research

Differential effect of ticagrelor versus clopidogrel by homocysteine levels on risk of recurrent stroke: a post hoc analysis of the CHANCE-2 trial
CMAJ. 2024 Feb 11;196(5):E149-E156. doi: 10.1503/cmaj.231262.ABSTRACTBACKGROUND: Elevated homocysteine levels are associated with increased blood coagulation and platelet activity and may modulate the response to antiplatelet therapies. We aimed to investigate the effects of homocysteine levels on the efficacy and safety of ticagrelor-acetylsalicylic acid (ASA) versus clopidogrel-ASA among patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles.METHODS: We conducted a post hoc analysis of the CHANCE-2 (The Clopidogrel in High-risk Patients with Acute Nondisabling Cerebrovascular...
Source: Canadian Medical Association Journal - February 12, 2024 Category: General Medicine Authors: Anxin Wang Xue Tian Xuewei Xie Hao Li Philip M Bath Jing Jing Jinxi Lin Yilong Wang Xingquan Zhao Zixiao Li Liping Liu Yongjun Wang Xia Meng Source Type: research

Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy
ConclusionIn the clinical setting it is feasible to use differentiated platelet analytics to determine alterations caused by antiplatelet therapy. Among the tests under investigation, PFA-200 showed the highest sensitivity for the intake of ASA in stroke patients. FACS analysis on the other hand might be able to provide a more nuanced approach to altered platelet reactivity. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - February 12, 2024 Category: Neurology Source Type: research